^
    6ms
    Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov)
    P1, N=117, Completed, Boston Pharmaceuticals | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Sep 2023 | Trial primary completion date: Mar 2024 --> Sep 2023
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    zeteletinib (BOS-172738)
    1year
    Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov)
    P1, N=117, Active, not recruiting, Boston Pharmaceuticals | Trial completion date: Apr 2023 --> Aug 2024 | Trial primary completion date: Apr 2023 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    zeteletinib (BOS-172738)
    over1year
    Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov)
    P1, N=117, Active, not recruiting, Boston Pharmaceuticals | Trial completion date: Dec 2022 --> Apr 2023 | Trial primary completion date: Dec 2022 --> Apr 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    zeteletinib (BOS-172738)
    2years
    Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov)
    P1, N=117, Active, not recruiting, Boston Pharmaceuticals | Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    zeteletinib (BOS-172738)
    over2years
    Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov)
    P1, N=117, Active, not recruiting, Boston Pharmaceuticals | Trial primary completion date: Dec 2021 --> Jun 2022
    Clinical • Trial primary completion date
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    zeteletinib (BOS-172738)
    over2years
    Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov)
    P1, N=117, Active, not recruiting, Boston Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Jun 2022
    Clinical • Enrollment closed • Trial completion date
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    zeteletinib (BOS-172738)
    3years
    [VIRTUAL] BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results. (ASCO 2021)
    BOS172738 is a highly potent and selective RET inhibitor with a differentiated safety profile and clinical activity against RET-altered tumors, including patients with brain metastases . BOS172738 continues to be evaluated in patients with NSCLC, MTC, and in patients previously treated with other selective RET inhibitors.
    P1 data
    |
    RET (Ret Proto-Oncogene) • KDR (Kinase insert domain receptor)
    |
    RET fusion • RET mutation
    |
    zeteletinib (BOS-172738)
    over3years
    Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors (clinicaltrials.gov)
    P1, N=114, Recruiting, Boston Pharmaceuticals | Trial completion date: Jun 2021 --> Nov 2021 | Trial primary completion date: Dec 2020 --> Nov 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation
    |
    zeteletinib (BOS-172738)